In situ editing of tumour cell membranes induces aggregation and capture of PD-L1 membrane proteins for enhanced cancer immunotherapy

Chunping Mao, Fu‐An Deng, Wenhao Zhu, Leiming Xie, Yijun Wang, Guoyin Li, Xiande Huang, Jiahui Wang, Yue Song, Ping Zeng, Zhenpeng He, Jingnan Guo, Yao Suo, Yujing Liu, Zhuo Chen, Mingxi Yao, Lu Zhang, Jun ShenNature Communications 2024 · DOI

Abstract

Immune checkpoint blockade (ICB) therapy has emerged as a new therapeutic paradigm for a variety of advanced cancers, but wide clinical application is hindered by low response rate. Here we use a peptide-based, biomimetic, self-assembly strategy to generate a nanoparticle, TPM1, for binding PD-L1 on tumour cell surface. Upon binding with PD-L1, TPM1 transforms into fibrillar networks in situ to facilitate the aggregation of both bound and unbound PD-L1, thereby resulting in the blockade of the PD-1/PD-L1 pathway. Characterizations of TPM1 manifest a prolonged retention in tumour ( > 7 days) and anti-cancer effects associated with reinvigorating CD8<sup>+</sup> T cells in multiple mice tumour models. Our results thus hint TPM1 as a potential strategy for enhancing the ICB efficacy.
BibTeX
@inproceedings{mao2024situ,
  author = {Chunping Mao and Fu‐An Deng and Wenhao Zhu and Leiming Xie and Yijun Wang and Guoyin Li and Xiande Huang and Jiahui Wang and Yue Song and Ping Zeng and Zhenpeng He and Jingnan Guo and Yao Suo and Yujing Liu and Zhuo Chen and Mingxi Yao and Lu Zhang and Jun Shen},
  title = {{In situ editing of tumour cell membranes induces aggregation and capture of PD-L1 membrane proteins for enhanced cancer immunotherapy}},
  booktitle = {Nature Communications},
  year = {2024},
  doi = {10.1038/s41467-024-54081-9},
}

Loading related content...

Figure